IP 3 – HOW WILL PATIENT CENTRICITY BE CAPTURED IN THE JAPANESE HTA AND HEALTHCARE REFORM?

Moderator: Adrian Towse,  
Director, Office of Health Economics  
Visiting Professor, London School of Economics  
www.ohe.org; atowse@ohe.org

Panellists and topics

• Professor Shunya Ikeda MD, International University of Health and Welfare, Narita City  
  • View from the Japanese Academic Side

• Makoto Kobayashi PhD, Director and CEO, CRECON Medical Assessment, Tokyo  
  • View from the Industry

• Durhane Wong-Rieger PhD, President and CEO, Canadian Organization for Rare Disorders  
  • Patient Perspective on Patient Centricity in Healthcare Decision Making (including HTA)
Questions

• In what way is the patient involved and engaged in decision making overseas? What are the benefits, especially in terms of understanding value, broader decision frameworks and access to new medicines?

• How does this compare to the current patient engagement and practices in Japan?

• What challenges would need to be overcome in Japan to better involve the patient voice in the emerging Japanese HTA reforms? How?

• What type of collaborative approaches and evidence generation platforms could be conducive for better patient data capture? Who is, or should be engaged in these activities?

• What are the benefits for Japanese HTA to embed patient centricity and how can this be accomplished?

• What training and support can Japanese HTA offer to patient groups to ensure informed patient engagement?